Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sen Han

Showing results (171-180 of 192) with videos related to

Pageof 20
Sort By:
JCI Insight|August 23, 2021
The role of SHP/REV-ERBα/CYP4A axis in the pathogenesis of alcohol-associated liver diseaseZhihong Yang, Rana V Smalling, Yi Huang, et al.
Research (Washington, D.C.)|January 20, 2025
Deep Learning-Enabled Integration of Histology and Transcriptomics for Tissue Spatial Profile AnalysisYongxin Ge, Jiake Leng, Ziyang Tang, et al.
Hepatology (Baltimore, Md.)|March 12, 2021
Stress-Responsive Gene FK506-Binding Protein 51 Mediates Alcohol-Induced Liver Injury Through the Hippo Pathway and Chemokine (C-X-C Motif) Ligand 1 SignalingPraveen Kusumanchi, Tiebing Liang, Ting Zhang, et al.
Oncotarget|July 25, 2016
A novel anti-PSMA human scFv has the potential to be used as a diagnostic tool in prostate cancerDonghui Han, Jieheng Wu, Yueheng Han, et al.
Alcohol and Alcoholism (Oxford, Oxfordshire)|March 25, 2021
Hepatic Histopathology Among Excessive Drinkers Without Advanced Liver DiseaseBinxia Chang, Ang Huang, Romil Saxena, et al.
Hepatology Communications|February 8, 2022
Transcriptomic Analysis Reveals the Messenger RNAs Responsible for the Progression of Alcoholic CirrhosisZhihong Yang, Sen Han, Ting Zhang, et al.
Heliyon|February 23, 2024
Real-world data on the first-line immune checkpoint inhibitors or in combination with chemotherapy in older patients (aged ≥ 75 years) with advanced non-small cell lung cancerPanpan Zhang, Minting Ma, Jun Nie, et al.
Asia-Pacific Journal of Clinical Oncology|January 29, 2026
Treatment Efficacy, Chemoradiotherapy Benefits, and Survival Disparities by Histology in Primary Mediastinal Germ Cell Tumors: 15-Year Results of a Single-Center Cohort StudyDi Wu, Ziran Zhang, Jun Nie, et al.
Asia-Pacific Journal of Clinical Oncology|March 25, 2018
Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLCDi Wu, Li Liang, Ligong Nie, et al.
Clinical Lung Cancer|January 10, 2026
Cumulative Incidence and Type-Specific Risk Factors of Pneumonitis After Definitive Chemoradiotherapy With or Without Immunotherapy in Locally Advanced Non-Small Cell Lung CancerJiawen Sun, Xin Dong, Zhixue Fu, et al.
Pageof 20

Showing results (171-180 of 192) with videos related to

Sort By:
Pageof 20
JCI Insight|August 23, 2021
The role of SHP/REV-ERBα/CYP4A axis in the pathogenesis of alcohol-associated liver diseaseZhihong Yang, Rana V Smalling, Yi Huang, et al.
Research (Washington, D.C.)|January 20, 2025
Deep Learning-Enabled Integration of Histology and Transcriptomics for Tissue Spatial Profile AnalysisYongxin Ge, Jiake Leng, Ziyang Tang, et al.
Hepatology (Baltimore, Md.)|March 12, 2021
Stress-Responsive Gene FK506-Binding Protein 51 Mediates Alcohol-Induced Liver Injury Through the Hippo Pathway and Chemokine (C-X-C Motif) Ligand 1 SignalingPraveen Kusumanchi, Tiebing Liang, Ting Zhang, et al.
Oncotarget|July 25, 2016
A novel anti-PSMA human scFv has the potential to be used as a diagnostic tool in prostate cancerDonghui Han, Jieheng Wu, Yueheng Han, et al.
Alcohol and Alcoholism (Oxford, Oxfordshire)|March 25, 2021
Hepatic Histopathology Among Excessive Drinkers Without Advanced Liver DiseaseBinxia Chang, Ang Huang, Romil Saxena, et al.
Hepatology Communications|February 8, 2022
Transcriptomic Analysis Reveals the Messenger RNAs Responsible for the Progression of Alcoholic CirrhosisZhihong Yang, Sen Han, Ting Zhang, et al.
Heliyon|February 23, 2024
Real-world data on the first-line immune checkpoint inhibitors or in combination with chemotherapy in older patients (aged ≥ 75 years) with advanced non-small cell lung cancerPanpan Zhang, Minting Ma, Jun Nie, et al.
Asia-Pacific Journal of Clinical Oncology|January 29, 2026
Treatment Efficacy, Chemoradiotherapy Benefits, and Survival Disparities by Histology in Primary Mediastinal Germ Cell Tumors: 15-Year Results of a Single-Center Cohort StudyDi Wu, Ziran Zhang, Jun Nie, et al.
Asia-Pacific Journal of Clinical Oncology|March 25, 2018
Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLCDi Wu, Li Liang, Ligong Nie, et al.
Clinical Lung Cancer|January 10, 2026
Cumulative Incidence and Type-Specific Risk Factors of Pneumonitis After Definitive Chemoradiotherapy With or Without Immunotherapy in Locally Advanced Non-Small Cell Lung CancerJiawen Sun, Xin Dong, Zhixue Fu, et al.
Pageof 20